Annex 1 is a starting point, not a finish line: How to go beyond compliance for future-ready aseptic processes

GMP Annex 1, the Manufacture of Sterile Medicinal Products, drives every aspect of how aseptic pharma manufacturing facilities are designed, run and inspected.

Since the revised regulation came fully into effect in 2023, manufacturers across the industry have been working through what it means for their processes. That work is still ongoing, and for good reason. How manufacturers interpret and achieve compliance to Annex 1 involves significant judgement.

Each organisation must assess what the guidance means for their specific operations, their facility design and their risk profile. That isn’t a failing of the regulation. Annex 1 is deliberately principles-based, and that flexibility is part of its strength.

But it does create a challenge: how confident can you be that your interpretation will hold up not just at your next inspection, but as regulatory expectations continue to evolve?

Regulatory focus shifts, the goalposts move

Annex 1, as a written regulation, doesn’t change frequently, but the pharma industry it governs is constantly evolving. As manufacturing processes, drug modalities and scientific understanding advance, so does the lens through which regulators assess compliance.

A decade ago, much of the regulatory conversation centred on particulate monitoring: demonstrating that cleanrooms and critical zones met particle count thresholds at rest and in operation. Over time, focus broadened to human intervention, recognising operator activity in and around aseptic processes as one of the most significant and variable sources of contamination.

More recently, first air protection has moved to the forefront, with regulators looking closely at whether unidirectional airflow is maintained over critical operations. And connecting all of these individual priorities is a growing emphasis on the contamination control strategy (CCS) as a whole.

Not just whether individual controls are in place, but whether they join up into a coherent, risk-based picture of how a facility identifies and manages contamination risk.

Each of these shifts reflects progress towards higher standards and greater patient safety. But they also mean that a system designed around one set of priorities can find itself under new scrutiny as expectations evolve. Treating Annex 1 compliance as a point-in-time checklist gives you a point-in-time answer.

It doesn’t tell you how resilient your processes are to the next evolution in regulatory thinking.

The weakest link in aseptic assurance

So where does that resilience get tested first? In our experience, the answer is often the same: transfer points.

Annex 1 identifies these moments where connections are made or broken as among the greatest risks for contamination. That aligns closely with what we see in practice. Manufacturers will often invest heavily in their core aseptic systems, and rightly so, but the transfer steps that feed into those systems don’t always receive the same depth of consideration. They may be compliant, but the level of confidence around them isn’t always on par with the confidence manufacturers have in larger, more visible investments like isolators and RABS.

This matters because transfer points sit at the intersection of equipment design, operator procedure, airflow management and validation. They are where multiple disciplines converge, and that convergence is where assumptions are most likely to go unchallenged. When regulatory focus shifts, as it has toward first air and CCS documentation, these are often the areas where gaps become visible first.

Some manufacturers address this by adding localised Grade A environments around transfer points to manage the risk. That can work, but can also mask inadequacies in other systems and process, with the grade A environment compensating for weaknesses rather than resolving them. In today’s pharma manufacturing landscape, where facilities are under pressure to do more with less space and tighter budgets, it adds cost, complexity and footprint that may not be sustainable. A better approach is to think about transfer risk holistically and embedding it into your CCS from the design phase, rather than addressing it in isolation.

This means asking from the outset: what level of protection does the connection itself provide, and how does that fit within the broader CCS?

Robust risk management, not over-specification

I’m not suggesting that every manufacturer should over-engineer their aseptic transfer systems on the off-chance that regulations might change. That’s not practical and it’s not good use of resources.

But there is a meaningful difference between designing to meet today’s minimum requirement and taking a robust, risk-based approach to how you think about aseptic transfer. The first gives you Annex 1 compliance today. The second gives you compliance today and confidence that your processes are repeatable, well-qualified and reliable, able to stand up as expectations evolve, without significant rework or retrofit.

In practice, that means asking harder questions during the design phase. Not just “does this meet the current requirement?” but “where are the residual risks in this process, and how would we respond if they came under greater scrutiny?” Here are some initial questions to consider:

• How does our transfer solution integrate with the facility’s airflow and first air protection?
• Does our validation approach account for the full lifecycle of the system, not just initial qualification?
• How do the transfer systems fit within our broader contamination control strategy?

These are the types of questions that get you thinking about validation as something your aseptic transfer system needs to support on an ongoing basis, not a one-off hurdle. They also highlight the importance of choosing equipment partners who are transparent about how their solutions are qualified, and who will support you through that journey, not just at the point of sale.

A different starting point

Annex 1 sets the expectation for a holistic, risk-based CCS. It is the foundation of safe, compliant aseptic pharma manufacturing. But it was never intended to be the finish line. The manufacturers best positioned for the future are those who embed that thinking deeply into their processes today, so they can stand up to the inspections of tomorrow.

It’s not an easy thing to do. But it’s the right thing to do.

If you’d like to discuss how to build future-proof confidence into your aseptic transfer processes, get in touch with us today.